Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Duolingo Inc (DUOL) Price & Performance

Charles River Laboratories Intl. IncTrade
Duolingo IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Duolingo Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.12 (market cap $14.23B), while Duolingo Inc trades at $150.16 (market cap $7.08B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2× Duolingo Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Duolingo Inc for 137 Days on average.

CRLDUOL
Market Cap
$14.23B$7.08B
Volume
1,176,885729,171
Sector
HealthTechnology
52-Week High
$310.77$341.08
52-Week Low
$149.93$90.03
Typical Hold Time
33 Days137 Days
Enterprise Value
$17.06B$5.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.

The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.

Duolingo Inc

Duolingo (DUOL) trades at $150.50, down 0.8% on the day, as the stock consolidates near key resistance at $151. The company demonstrates strong fundamental momentum with revenue reaching $1.04 billion in 2025 and net income surging to $414 million, representing a robust 39.9% margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Technical indicators show a bullish moving average alignment while RSI levels suggest potential near-term consolidation.

Duolingo presents a compelling growth story with accelerating profitability and strong user engagement, though valuation multiples remain elevated. Key risks include increased competition in edtech and insider selling activity. Analyst consensus leans cautious with a $140.63 price target below current levels, suggesting potential near-term headwinds despite the company's operational excellence.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRL
0% Buy100% Sell
Avg holding period · 33 Days
DUOL
23% Buy77% Sell
Avg holding period · 137 Days

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL →

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL →